NK
NKGen Biotech, Inc. Common Stock
NKGN · OTC
$0.01 +0.00% (+$0.00)
1M +471.43%
Market Cap $1.57M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
91 /100
Cheap P/S 2.40x
EV/EBITDA 1.85x
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 3,612.58%
Op. margin 3,682.67%
FCF margin 3,021.32%
Quality
58 /100
Average ROA 148.68%
Asset turnover 0.04x
ROIC 2,118.41%
Debt
45 /100
Moderate Int. coverage 3.08x
Net debt/EBITDA 1.77x
Current ratio 0.05x
Stability
37 /100
Moderate EPS volatility 211.35%
Profitable years 0
Beta 0.72x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o NKGN
Online
O spółce
NKGen Biotech, Inc. Common Stock (NKGEN) is a biotechnology company specializing in the development and research of therapeutic products utilizing natural killer (NK) cells. Their main focus is on harnessing the body's immune system to fight against cancer and other diseases.
Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Y. Song
Employees
26
Headquarters
Santa Ana